Tykerb and Pepcid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tykerb (lapatinib ditosylate) and Pepcid (famotidine). Common drug interactions include anaemia among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Tykerb and Pepcid. It is created by eHealthMe based on reports of 52 people who take the same drugs from the FDA, and is updated regularly.

What is Tykerb?

Tykerb has active ingredients of lapatinib ditosylate. It is often used in breast cancer. eHealthMe is studying from 12,231 Tykerb users. Check the latest studies of Tykerb.

What is Pepcid?

Pepcid has active ingredients of famotidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 55,774 Pepcid users. Check the latest studies of Pepcid.



On Jul, 28, 2026

52 people who take Tykerb and Pepcid together, and have interactions are studied.

Tykerb and Pepcid drug interactions.

What are the common drug interactions of Tykerb and Pepcid, by gender? *:

female:

  1. Anaemia (lack of blood)
  2. Anxiety
  3. Atelectasis (partial or complete collapse of the lung)
  4. Bone pain
  5. Dry eye (lack of adequate tears)
  6. Dyspnoea (difficult or laboured respiration)
  7. Hepatic lesion
  8. Injury
  9. Metastases to bone (cancer spreads to bone)
  10. Metastases to lymph nodes (cancer spreads to lymph node)

male:

  1. Nausea (feeling of having an urge to vomit)
  2. Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
  3. Bone pain
  4. Cardiac tamponade (fluid accumulates in heart covering)
  5. Cardiomegaly (increased size of heart than normal)
  6. Cataract (clouding of the lens inside the eye)
  7. Cerebral cyst (fluid filled tumour of brain)
  8. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  9. Chest pain
  10. Clavicle fracture

What are the common drug interactions of Tykerb and Pepcid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Abdominal pain lower
  2. Abortion spontaneous (naturally occurring miscarriage)
  3. Breast pain
  4. Cough
  5. Diarrhoea
  6. Drug ineffective
  7. Dysphagia (a condition in which swallowing is difficult or painful)
  8. Epistaxis (bleed from the nose)
  9. Human chorionic gonadotropin decreased
  10. Ingrowing nail

40-49:

  1. Asthenia (weakness)
  2. Hypoaesthesia (reduced sense of touch or sensation)
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  4. Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
  5. Erythema (redness of the skin)
  6. Hepatic failure (liver failure)
  7. Nausea (feeling of having an urge to vomit)
  8. Necrosis (the death of body tissue)
  9. Skin discolouration (change of skin colour)
  10. Skin disorder (skin disease)

50-59:

  1. Oedema peripheral (superficial swelling)
  2. Vomiting
  3. Alopecia (absence of hair from areas of the body)
  4. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  5. Anaemia (lack of blood)
  6. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  7. Anxiety
  8. Asthenia (weakness)
  9. Atelectasis (partial or complete collapse of the lung)
  10. Bone pain

60+:

  1. Diarrhoea
  2. Fatigue (feeling of tiredness)
  3. Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
  4. Anaemia (lack of blood)
  5. Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
  6. Anxiety
  7. Aortic valve incompetence
  8. Arachnoid cyst
  9. Arthropathy
  10. Atelectasis (partial or complete collapse of the lung)

What are the existing conditions these people have? *

  1. Breast Cancer Metastatic: 7 people, 13.46%

* Approximation only. Some reports may have incomplete information.

Do you take Tykerb and Pepcid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tykerb and Pepcid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tykerb:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pepcid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tykerb and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pepcid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lapatinib ditosylate and famotidine (the active ingredients of Tykerb and Pepcid, respectively), and Tykerb and Pepcid (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: